Highlights of the GU Cancers Symposium
The March issue features coverage of the 2012 Genitourinary (GU) Cancers Symposium, which was held in San Francisco.
The March issue features coverage of the 2012 Genitourinary (GU) Cancers Symposium, which was held in San Francisco.
Although a detailed trend analysis of 127,614 U.S. cases of first primary bladder cancer demonstrated a 9% overall drop in disease occurrence between 1973 and 2007, papillary transitional cell carcinoma (PTCC)—one of two main subtypes—increased by 56% over that period.
In an international study of 1,635 emergency-department patients, urinary neutrophil gelatinase-associated lipocalin (uNGAL) was the most useful of five urinary biomarkers in predicting the severity and duration of acute kidney injury (AKI) at the time of hospital admission, with 81% specificity and 68% sensitivity at a cutoff of 104 ng/mL.
Dietary calcium is associated with lower risk for prostate cancer (PCa), particularly among black men, and with a lower risk for high-grade prostate cancer among all men, according to a study involving 108 U.S. veterans with biopsy-positive prostate cancer, 161 biopsy-negative controls, and 237 healthy controls.
LONDON—Low-risk non-muscle invasive bladder cancer (NMIBC) could be safely managed by periods of active surveillance rather than aggressive resection surgery and frequent cystoscopic follow up.
LONDON—Cryotherapy can be used to treat small renal tumors or masses successfully with relatively low rates of complications and recurrence, a urologist skilled in the technique told attendees at the Renal and Bladder Cancer 3rd National conference here.
For some, freedom from the hassles of treatment is worth a shorter life expectancy, study finds.
Pulmonary hypertension is common in hemodialysis (HD) patients and it is associated with an increased death risk, a study found.
Living kidney donors are at no higher risk for requiring acute dialysis than non-donors, according to a study conducted in Canada and the United States.
SAN FRANCISCO—Everolimus is the first potential pharmacologic treatment option for patients with angiomyolipoma (AML), a benign tumor that usually occurs in the kidney, researchers reported at the 2012 Genitourinary Cancers Symposium.